Selecta Biosciences (SELB) Tops Q4 EPS by 10c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Selecta Biosciences Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
March 10, 2022 8:00 AM ESTU.S. Food and Drug Administration (FDA) removed clinical hold on SEL-302 for the treatment of patients with methylmalonic acidemia (MMA)-
-Observed the synergy of ImmTOR in combination with engineered Treg-selective IL-2 to expand antigen-specific Tregs and improve durability of immune tolerance (ImmTOR-IL)-
-Further validated and expanded the ImmTOR precision immune tolerance platform through numerous strategic collaborations -
-Completed enrollment in DISSOLVE I, the first of two studies in the Phase 3 program evaluating SEL-212 for chronic refractory gout-
... More